Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Ryzodeg is indicated for:
Pharmacology
Insulin degludec and insulin aspart bind specifically to the human insulin receptor, and they produce the same pharmacological effects as human insulin. Insulin lowers blood glucose because, once it binds to receptors on muscle and fat cells, those cells take up glucose more easily. At the same time, it stops the liver from releasing glucose.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
This premixed Insulin Degludec + Insulin Aspart product is a soluble insulin made of degludec, a basal insulin, and aspart, a rapid-acting prandial insulin. This is dosed according to each patient's own needs, and dose changes are mainly based on fasting plasma glucose measurements. For patients with type 2 diabetes mellitus, the recommended total daily starting dose is 10 units with meal(s), and the dose is then adjusted for the individual. For patients with type 1 diabetes mellitus, the recommended starting dose is 60 to 70% of the total daily insulin requirements. This is used once daily at meal-time, in combination.
Side Effects
Insulin Degludec + Insulin Aspart Premixed can cause hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain.
Cautions & Contraindications
Warnings & Precautions
Hypoglycaemia: Omission of a meal or unplanned strenuous physical exercise may lead to hypoglycaemia. It may also happen if the insulin dose is too high for the insulin the patient actually needs. Concomitant illness, especially infections and fever, usually increases the patient's insulin requirement. Concomitant diseases of the kidney or liver, or diseases affecting the adrenal, pituitary or thyroid gland, may call for a change in the insulin dose. Hyperglycaemia: Administration of rapid-acting insulin is recommended in situations with severe hyperglycaemia. Inadequate dosing and/or discontinuation of treatment in patients who need insulin may lead to hyperglycaemia and possibly to diabetic ketoacidosis. Concomitant illness, especially infections, can also lead to hyperglycaemia, and this raises the insulin requirement. Eye disorder: Intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy. Long-term improved glycaemic control, on the other hand, decreases the risk of progression of diabetic retinopathy. Avoidance of accidental mix-ups: Patients must be instructed to always check the insulin label before each injection, so that this insulin is not mixed up with other insulin products. Older patients (> 65 years old): Insulin Degludec & Insulin Aspart Premixed can be used in older patients. Glucose monitoring is to be intensified and the insulin dose adjusted on an individual basis. Paediatric population: This insulin has been given to children and adolescents up to 18 years of age for the investigation of pharmacokinetic properties. Safety and efficacy have not been investigated in children and adolescents.
Pregnancy & Breastfeeding
Insulin Degludec + Insulin Aspart Premixed is Pregnancy Category C. Animal reproduction studies have shown an adverse effect on the fetus, and there are no adequate and well-controlled studies in humans. Even so, the potential benefits may warrant use of the medicine in pregnant women despite the potential risks.
There are no data on whether insulin degludec is present in human milk, what effect it has on a breastfed infant, or what effect it has on milk production. Insulin degludec is present in rat milk. One small published study reported that exogenous insulin, including insulin aspart, was present in human milk. But there is not enough information to say what effects insulin aspart has on the breastfed infant, and no information is available on its effects on milk production.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Use in Special Populations
Renal and hepatic impairment
Insulin Degludec + Insulin Aspart Premixed can be used in people with kidney or liver impairment. Blood glucose needs to be monitored more closely in these patients, and the insulin dose adjusted for each person individually.
Common questions about Ryzodeg 100 IU/ml
What is Ryzodeg 100 IU/ml SC Injection?
Ryzodeg 100 IU/ml SC Injection is a medicine that contains Insulin Degludec + Insulin Aspart Premixed. It is made by Novo Nordisk Pharma (Pvt.) Ltd. It belongs to the Combination Insulin group of medicines.
What is Ryzodeg used for?
Ryzodeg is used for: Diabetes Mellitus.
What are the side effects of Ryzodeg?
Insulin Degludec + Insulin Aspart Premixed can cause hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain.
Can I take Ryzodeg during pregnancy or while breastfeeding?
Insulin Degludec + Insulin Aspart Premixed is Pregnancy Category C. Animal reproduction studies have shown an adverse effect on the fetus, and there are no adequate and well-controlled studies in humans. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Do I need a prescription for Ryzodeg?
Ryzodeg is a prescription (Rx) medicine. Take it as your doctor advises.